FindTrial
Sign In

L-PLUS1 study

Phase 3 study of S-888711 in thrombocytopenic patients with chronic liver disease

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222274
Enrollment
Unknown
Registered
2013-11-01
Start date
2013-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenia due to chronic liver disease

Interventions

investigational material(s) Generic name etc : S-888711 INN of investigational material : Lusutrombopag Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Admin

Sponsors

SHIONOGI & CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Main inclusion criteria: Thrombocytopenic patients with chronic liver disease undergoing invasive procedures.

Exclusion criteria

Exclusion criteria: Main exclusion criteria: Patients who received blood transfusions (except for red blood cell products and albumin preparations) within 14 days prior to enrollment. Patients who previously received TPO receptor agonists.

Design outcomes

Primary

MeasureTime frame
Efficacy, safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026